$22.00 -0.78 (-3.42%)
11/6/2009 4:02 PM

Par Pharmaceutical Companies, Inc. (PRX)

CAPS Rating: 3 out of 5

The Company, through its subsidiary Par Pharmaceutical, Inc., is engaged in the development, manufacture and distribution of generic pharmaceuticals and branded pharmaceuticals in the United States.

Current Price $22.00 Mkt Cap $764.91M
Open $23.50 P/E Ratio 55.56
Prev. Close $22.78 Div. (Yield) N/A (N/A)
Daily Range $21.78 - $23.67 Volume 1,541,278
52-Wk Range $7.91 - $24.23 Avg. Daily Vol. 465,000

PRX News and Commentary

Caps

How do you think PRX will perform vs the S&P 500?

Add Stock to Watchlist

All Members

145 Outperform
20 Underperform
 

All-Star Members

45 Outperform
3 Underperform
 

Wall Street

5 Outperform
2 Underperform
 

Top PRX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

00746angel (< 20)
Submitted February 19, 2007

shipping out new approved drugs
as fast as they can produce them
pipe lines need to be filled
also esclusive rights for six months

0 Comments | Reply | Report this Post

dustbusterz (< 20)
Submitted August 24, 2007

wow - take a look at the stats on this company. right at the moment, it appears to be beating the market as far as stock appreciation goes, but this baffles me . they have a net loss on growth,net loss on profit margins,operating margins are slim to… More

0 Comments | Reply | Report this Post
PRX VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about PRX.

Recs

0
Member Avatar IBDvalueinvestin (96.37) Submitted: 11/6/2009 11:31:16 AM : Outperform Start Price: $23.50 PRX Score: -7.20

PRX looking to get approvals on an additional $6.5B worth of drugs.

PRX Total revenue nearly doubled to $294.8 million

Analysts on average expected earnings of 49 cents a share on revenue of $290.4 million, according to Thomson Reuters I/B/E/S.

PRX said it currently has about 27 abbreviated new drug applications pending with the U.S. health regulators, 13 of which the company believes have first-to-file or first-to-market opportunities with a brand value of about $6.5 billion.

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar EBStroke (< 20) Submitted: 10/23/2009 3:00:08 PM : Outperform Start Price: $21.48 PRX Score: +3.02

Zacks Rank 1-StrongBuy, Recommend Outperform, Industry Rank 16 / 217, Target 25.20, Avg Target of 7 analysts 26.33
Floor 21.35, Ceiling 26.00

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar CatTrades (34.25) Submitted: 10/17/2009 12:03:25 AM : Outperform Start Price: $23.29 PRX Score: -3.76

Aging population will need generic pills regardless of government interference. Cash flow is a little weak, but the rest looks pretty good.

Report this Post 0 Comments | Reply | Permalink
View All 25 Pitches »

Leaderboard

Find the members with the highest scoring picks in PRX.

Score Leader

TrackCarisandCo

TrackCarisandCo (78.62) Score: +93.94

The Score Leader is the member with the highest score across all their picks in PRX.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
BBQPrinceofPork 25.75 7/7/2006 Outperform 5Y $13.03 +68.84% -10.41% +79.25
TheHague 76.43 4/9/2009 Outperform NS $10.87 +102.39% +27.85% +74.54 1 Comment
Superman2bad4u 76.33 4/29/2009 Outperform 5Y $11.19 +96.60% +23.71% +72.90 1 Comment
ellistea1024 < 20 3/23/2009 Outperform NS $10.64 +106.77% +37.48% +69.29
wepencryption < 20 3/23/2009 Outperform NS $10.64 +106.77% +37.48% +69.29
runtheworld 97.42 4/20/2009 Outperform 1Y $11.35 +93.83% +26.54% +67.29
TMFEldrehad 99.99 7/7/2006 7/27/2009 Outperform 3Y $14.00 +57.14% -10.15% +67.29
stevez24 82.20 3/26/2009 Outperform 3M $11.05 +99.10% +31.87% +67.23 1 Comment
SSPX1 89.29 5/7/2009 Outperform NS $11.99 +83.49% +16.39% +67.10
SSPX7 25.51 5/8/2009 Outperform NS $11.92 +84.56% +17.62% +66.94
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackBarclaysCap 86.02 10/16/2009 Outperform NS $22.98 -4.26% -1.52% -2.75
TrackCarisandCo 78.62 11/10/2008 Outperform NS $10.45 +110.53% +16.59% +93.94
TrackNeedham < 20 9/25/2008 Outperform NS $13.00 +69.23% -8.03% +77.26
TrackJPMorgan 78.71 3/4/2008 Underperform NS $18.60 +18.28% -15.57% -33.85
TrackFBRCapitalM 75.98 10/1/2007 Underperform NS $17.67 +8.49% -12.80% -21.29 2/8/2008 @ $19.17
TrackSoros 65.62 9/30/2007 Outperform NS $18.56 +18.53% -26.44% +44.97 1 Comment
TrackLeerinkSwan 84.26 5/21/2007 Outperform NS $28.78 -23.56% -25.77% +2.21
TrackJimCramer < 20 2/5/2007 Underperform 3W $26.89 -18.19% -21.50% -3.31
TrackLehmanBros 76.60 11/22/2006 Outperform NS $19.73 +4.05% +5.45% -1.39 12/13/2007 @ $20.53

Featured Broker Partners